Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes

Hans H. Wandall, Ola Blixt, Mads A. Tarp, Johannes W. Pedersen, Eric P. Bennett, Ulla Mandel, Govind Ragupathi, Phil O. Livingston, Michael A. Hollingsworth, Joyce Taylor-Papadimitriou, Joy Burchell, Henrik Clausen

Research output: Contribution to journalArticlepeer-review

212 Scopus citations


Autoantibodies to cancer antigens hold promise as biomarkers for early detection of cancer. Proteins that are aberrantly processed in cancer cells are likely to present autoantibody targets. The extracellular mucin MUC1 is overexpressed and aberrantly glycosylated in many cancers; thus, we evaluated whether autoantibodies generated to aberrant O-glycoforms of MUC1 might serve as sensitive diagnostic biomarkers for cancer. Using an antibody-based glycoprofiling ELISA assay, we documented that aberrant truncated glycoforms were not detected in sera of cancer patients. An O-glycopeptide microarray was developed that detected IgG antibodies to aberrant O-glycopeptide epitopes in patients vaccinated with a keyhole limpet hemocyanin-conjugated truncated MUC1 peptide. We detected cancer-associated IgG autoantibodies in sera from breast, ovarian, and prostate cancer patients against different aberrent O-glycopeptide epitopes derived from MUC1. These autoantibodies represent a previously unaddressed source of sensitive biomarkers for early detection of cancer. The methods we have developed for chemoenzymatic synthesis of O-glycopeptides on microarrays may allow for broader mining of the entire cancer O-glycopeptidome.

Original languageEnglish (US)
Pages (from-to)1306-1313
Number of pages8
JournalCancer Research
Issue number4
StatePublished - Feb 15 2010

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes'. Together they form a unique fingerprint.

Cite this